Federico Pichardo
New York, NYNPI 1821213448
Payments from drug & device makers
Across 703 payments — averaging $22.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- Novo Nordisk$2K
- AstraZeneca$1K
- Boehringer Ingelheim$1K
- Biohaven Pharmaceuticals, Inc.$931
- plus $7K from 39 others
What the payments were for
- Consulting fees$8005%
- Food & beverage$14,78994%
- Education$851%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$800
- RYBELSUS$346
- XIFAXAN$256
- Reltone 200 Mg$256
- GLYCATE$256
- Reltone 400 Mg$256
- AIRSUPRA$249
- LOKELMA$238
- Omnipod$165
- IBSRELA$150
- RECORLEV$150
- TRULANCE$140
- GVOKE HYPOPEN$124
- AREXVY$118
- Kerendia$118
- XARELTO$115
- CAPLYTA$114
- Ozempic$106
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VascepaIcosapent Ethyl | 240 | $161,886 |
| JanuviaSitagliptin Phosphate | 134 | $145,700 |
| RybelsusSemaglutide | 90 | $142,109 |
| FarxigaDapagliflozin Propanediol | 102 | $136,996 |
| OzempicSemaglutide | 88 | $126,954 |
| LinzessLinaclotide | 114 | $119,423 |
| JanumetSitagliptin Phos/Metformin Hcl | 100 | $112,766 |
| JardianceEmpagliflozin | 83 | $106,513 |
| TrulicityDulaglutide | 60 | $92,546 |
| MyrbetriqMirabegron | 76 | $61,428 |
| TradjentaLinagliptin | 49 | $60,314 |
| EliquisApixaban | 48 | $57,290 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 37 | $42,555 |
| CreonLipase/Protease/Amylase | 33 | $39,635 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $28,690 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $1,523 | $269,064178 claims |
| MerckJanuvia, Janumet, Janumet Xr | $20 | $264,933246 claims |
| AbbVieLinzess, Creon, Restasis, Combigan | $2,234 | $187,329181 claims |
| Boehringer IngelheimJardiance, Tradjenta, Jentadueto | $1,079 | $182,096147 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,259 | $179,550139 claims |
| Lilly USA, LLCTrulicity | $110 | $92,54660 claims |
| Astellas Pharma US IncMyrbetriq | $462 | $61,42876 claims |
| PfizerEliquis | $243 | $57,29048 claims |
| GSKTrelegy Ellipta | $449 | $28,69030 claims |
| NovartisEntresto | $338 | $25,23617 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $1,845 | $20,39917 claims |
| Johnson & JohnsonXarelto | $324 | $17,59712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in New Yorkon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.